Cell Biotech Co

Cell Biotech Co LT Debt/Equity

Long-Term Debt to Equity Ratio of Cell Biotech Co (049960.KQ) as of Nov 17, 2026.

LT Debt/Equity

0.00

YoY

-64.63%

Last updated:

Long-Term Debt to Equity Ratio of Cell Biotech Co is 2024 0.00 . Long-Term Debt to Equity Ratio of Cell Biotech Co was 2023 0.01 . It decreases by -64.63% lower compared to the previous year.

The Cell Biotech Co LT Debt/Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

LT Debt/Equity
Date
LT Debt/Equity
Jan 1, 2017
0.00 KRW
Jan 1, 2018
0.00 KRW
Jan 1, 2019
0.00 KRW
Jan 1, 2020
0.01 KRW
Jan 1, 2021
0.00 KRW
Jan 1, 2022
0.00 KRW
Jan 1, 2023
0.01 KRW
Jan 1, 2024
0.00 KRW
The Cell Biotech Co LT Debt/Equity history
YEARLT Debt/EquityYoY
0.00-64.63%
0.01+152.24%
0.00-16.61%
0.00-42.18%
0.01+38.90%
0.00—
0.00—
0.00—
0.00—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cell Biotech Co Stock analysis

What does Cell Biotech Co do? Cell Biotech Co., Ltd. generates revenue through the production and sale of probiotic lactobacillus products. The company manufactures lactic acid bacteria (LAB) powders, which serve as raw materials for foods and medicines targeting immunization enhancement and digestion improvement. Finished products containing LABs are sold for intestinal health improvement, carcinogen inhibition, and calcium supplementation, distributed domestically and internationally. The firm focuses on functional health applications within the probiotics market. The company's primary customers are domestic and international food and pharmaceutical manufacturers seeking functional ingredients, as well as end consumers purchasing finished probiotic products. LAB powders are supplied to food and medicine producers, while finished products reach consumers directly for health benefits. Distribution channels include both local and global markets, emphasizing the functional health segments of the industry. Cell Biotech's product portfolio centers on LAB-based solutions for health enhancement, with no additional brands or external partnerships mentioned in the business description. The company operates solely within the probiotics sector, leveraging its research and development capabilities to create products aligned with digestive and immune health needs. Cell Biotech Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Cell Biotech Co stock

On Eulerpool you can find the complete historical development of Long-Term Debt to Equity Ratio Cell Biotech Co since 2006 – with annual values, charts, and detailed analysis.

The LT Debt/Equity ratio measures long-term financial leverage. It shows how much permanent debt capital is used relative to equity financing.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Long-Term Debt to Equity Ratio's Cell Biotech Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Cell Biotech Co

All Key Metrics — Cell Biotech Co